US 12,006,303 B2
Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said substituted indazoles, and use of said substituted indazoles to produce drugs
Ulrich Bothe, Berlin (DE); Holger Siebeneicher, Berlin (DE); Nicole Schmidt, San Francisco, CA (US); Reinhard Nubbemeyer, Berlin (DE); Ulf Bömer, Glienicke (DE); Judith Günther, Berlin (DE); Holger Steuber, Berlin (DE); Martin Lange, Berlin (DE); Christian Stegmann, Berlin (DE); Andreas Sutter, Berlin (DE); Alexandra Rausch, Berlin (DE); Christian Friedrich, Brandenburg (DE); and Peter Hauff, Berlin (DE)
Assigned to BAYER PHARMA AKTIENGESELLSCHAFT, Berlin (DE)
Filed by Bayer Pharma Aktiengesellschaft, Berlin (DE)
Filed on Jul. 20, 2022, as Appl. No. 17/869,673.
Application 17/869,673 is a continuation of application No. 17/009,553, filed on Sep. 1, 2020, abandoned.
Application 17/009,553 is a continuation of application No. 16/377,025, filed on Apr. 5, 2019, granted, now 10,793,545, issued on Oct. 6, 2020.
Application 16/377,025 is a continuation of application No. 15/529,996, granted, now 10,308,634, issued on Jun. 4, 2019, previously published as PCT/EP2015/077596, filed on Nov. 25, 2015.
Claims priority of application No. 14195032 (EP), filed on Nov. 26, 2014.
Prior Publication US 2023/0174508 A1, Jun. 8, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 401/12 (2006.01); A61K 31/4439 (2006.01); A61P 19/02 (2006.01); C07D 405/14 (2006.01); C07F 7/18 (2006.01)
CPC C07D 401/12 (2013.01) [A61K 31/4439 (2013.01); A61P 19/02 (2018.01); C07D 405/14 (2013.01); C07F 7/1804 (2013.01)] 24 Claims
 
1. A method for treating a dermatological disease or disorder in a human in need thereof, comprising administering to the human an effective amount of a compound of formula (I):

OG Complex Work Unit Chemistry
wherein:
R1 is C1-C6-alkyl, wherein the C1-C6-alkyl group is monosubstituted with an R7SO2 or R7SO2 group, or
wherein the C1-C6-alkyl group is polysubstituted with at least one of an R7SO2 group or R7SO group, and one or more additional substituents selected from the group consisting of halogen, hydroxyl, an unsubstituted or mono- or poly-halogen substituted C3-C6-cycloalkyl, an R6 group, and an R8O group;
R2 and R3 always have the same definition and are both either hydrogen or C1-C6-alkyl;
R4 is halogen, cyano, an unsubstituted or a singly or multiply, identically or differently substituted C1-C6-alkyl or an unsubstituted or a singly or multiply, identically or differently substituted C3-C6-cycloalkyl, and the substituents are selected from the group consisting of halogen and hydroxyl;
R5 is hydrogen, halogen or an unsubstituted or mono- or poly-halogen-substituted C1-C6-alkyl;
R6 is an unsubstituted or mono- or di-methyl-substituted monocyclic saturated heterocycle having 4 to 6 ring atoms, which contains a heteroatom or a heterogroup from the group of O, S, SO and SO2;
R7 is C1-C6-alkyl, where the C1-C6-alkyl group is unsubstituted or mono- or polysubstituted identically or differently by halogen, hydroxyl or C3-C6-cycloalkyl;
or R7 is C3-C6-cycloalkyl; and
R8 is C1-C6-alkyl, where the C1-C6-alkyl group is unsubstituted or mono- or polysubstituted identically or differently by halogen,
or a diastereomer, an enantiomer, a salt, a solvate, or a solvate of the salt thereof.